Omnicell (NASDAQ:OMCL) Given “Buy” Rating at Benchmark

Omnicell (NASDAQ:OMCL)‘s stock had its “buy” rating restated by analysts at Benchmark in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $48.00 price target on the stock. Benchmark’s price objective would indicate a potential upside of 11.29% from the stock’s previous close.

Other research analysts have also issued research reports about the stock. Barclays upgraded shares of Omnicell from an “underweight” rating to an “equal weight” rating and raised their price target for the stock from $26.00 to $39.00 in a report on Friday, August 2nd. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Thursday, September 19th. Wells Fargo & Company lifted their price objective on Omnicell from $26.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Friday, August 2nd. Bank of America upped their target price on Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Finally, JPMorgan Chase & Co. lifted their target price on Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a report on Friday, August 23rd. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Omnicell currently has a consensus rating of “Hold” and an average target price of $39.50.

Omnicell Trading Up 0.2 %

Shares of Omnicell stock traded up $0.09 during trading on Wednesday, hitting $43.13. The company’s stock had a trading volume of 18,873 shares, compared to its average volume of 524,311. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of -93.76, a price-to-earnings-growth ratio of 46.63 and a beta of 0.83. Omnicell has a 52 week low of $25.12 and a 52 week high of $46.05. The stock has a 50-day moving average price of $42.36 and a two-hundred day moving average price of $33.45. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.45 and a quick ratio of 2.22.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The firm had revenue of $276.80 million for the quarter, compared to analyst estimates of $254.41 million. During the same quarter in the previous year, the company posted $0.29 EPS. The business’s revenue was down 7.4% on a year-over-year basis. Equities research analysts anticipate that Omnicell will post 0.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Omnicell

Several hedge funds and other institutional investors have recently modified their holdings of OMCL. GAMMA Investing LLC grew its position in Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after purchasing an additional 553 shares during the period. Nisa Investment Advisors LLC raised its holdings in shares of Omnicell by 248.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after acquiring an additional 1,000 shares during the last quarter. EntryPoint Capital LLC lifted its position in Omnicell by 121.2% in the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after acquiring an additional 1,345 shares in the last quarter. CWM LLC boosted its stake in Omnicell by 68.2% during the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after purchasing an additional 1,236 shares during the last quarter. Finally, Benjamin Edwards Inc. boosted its stake in Omnicell by 36.4% during the 1st quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock valued at $95,000 after purchasing an additional 868 shares during the last quarter. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.